Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

Background Relatlimab plus nivolumab (anti–lymphocyte-activation gene 3 plus anti–programmed death 1 [anti–LAG-3+anti–PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.Methods We evaluated blood samples from...

Full description

Bibliographic Details
Main Authors: Jani Huuhtanen, Henna Kasanen, Katriina Peltola, Tapio Lönnberg, Virpi Glumoff, Oscar Brück, Olli Dufva, Karita Peltonen, Johanna Vikkula, Emmi Jokinen, Mette Ilander, Moon Hee Lee, Siru Mäkelä, Marta Nyakas, Bin Li, Micaela Hernberg, Petri Bono, Harri Lähdesmäki, Anna Kreutzman, Satu Mustjoki
Format: Article
Language:English
Published: American Society for Clinical Investigation 2023-03-01
Series:The Journal of Clinical Investigation
Subjects:
Immunology
Oncology
Online Access:https://doi.org/10.1172/JCI164809

Internet

https://doi.org/10.1172/JCI164809

Similar Items